Consun Pharmaceutical Group Limited executed an on-market share buyback on 28 May 2026, purchasing 115,000 ordinary shares at prices between HKD 13.88 and HKD 14.01, for a volume-weighted average of HKD 13.97 per share. The transaction totalled HKD 1.61 million.

Following the repurchase: • Issued shares outstanding (excluding treasury stock) fell 0.01 % to 841.09 million. • Treasury shares rose to 459,000, keeping total issued shares unchanged at 841.55 million.

Buy-backs were conducted under the mandate approved on 26 May 2026, which authorises repurchases of up to 84.12 million shares. The 115,000 shares bought to date represent 0.14 % of that limit.

No shares have been cancelled; the repurchased stock is held in treasury. Under Hong Kong Stock Exchange rules, Consun Pharma is subject to a moratorium on issuing, selling or transferring shares until 27 June 2026.

The company confirmed that the transactions complied with all applicable listing rules, regulatory requirements and the terms of its explanatory statement dated 28 April 2026.